Companies / Allogene Therapeutics, Inc. / Activity
Activity — Allogene Therapeutics, Inc.
10 moves.
Top impactInsider · CEO movesInsider · biggest buysInsider · biggest sellsInstitution · biggest movesInstitution · new positions
| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Feb 2, 2026 | David D. Chang, M.D., Ph.D. CEO | Sell | Common Stock | $171.5K | -95K -1.80% | 5,185,862 1.50% of shares | medium |
| Mar 16, 2026 | David D. Chang, M.D., Ph.D. CEO | Sell | Common Stock | $118.0K | -48K -0.92% | 5,150,599 1.49% of shares | medium |
| Feb 2, 2026 | Roberts Zachary Executive | Sell | Common Stock | $63.2K | -36K -5.79% | 581,166 0.17% of shares | low |
| Feb 2, 2026 | Parker Geoffrey M. Executive | Sell | Common Stock | $42.2K | -24K -1.88% | 1,252,795 0.36% of shares | low |
| Jan 21, 2026 | Roberts Zachary Executive | Sell | Common Stock | $41.0K | -26K -4.08% | 616,866 0.18% of shares | low |
| Feb 2, 2026 | Douglas Earl Martin Executive | Sell | Common Stock | $40.3K | -23K -3.90% | 564,948 0.16% of shares | low |
| Mar 2, 2026 | Beneski Benjamin Machinas Executive | Sell | Common Stock | $18.5K | -7K -3.39% | 203,040 0.06% of shares | low |
| Feb 2, 2026 | Beneski Benjamin Machinas Executive | Sell | Common Stock | $13.1K | -8K -3.47% | 210,172 0.06% of shares | low |
| Mar 16, 2026 | Beneski Benjamin Machinas Executive | Sell | Common Stock | $11.9K | -5K -2.38% | 198,205 0.06% of shares | low |
| Feb 2, 2026 | Yoshiyama Annie Executive | Sell | Common Stock | $7.2K | -4K -3.10% | 130,322 0.04% of shares | low |